Tesamorelin (5mg)

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) that works by prompting the body’s own pituitary gland to release growth hormone in a pulsatile, physiologic pattern — rather than supplying growth hormone directly. That increase in growth hormone then raises levels of insulin-like growth factor-1 (IGF-1), a hormone involved in cellular repair, metabolism, and body composition. This distinction is important: whereas exogenous growth hormone can overwhelm normal feedback loops, tesamorelin essentially restores a more youthful hormonal rhythm. Evergreen Institute

It received FDA approval in November 2010 under the brand name Egrifta, specifically for reducing excess abdominal fat in HIV-infected patients with lipodystrophy — a condition characterized by abnormal fat distribution common in those receiving antiretroviral therapy. Oath Peptides

Areas of Active Research:

1. Visceral Fat Reduction (HIV-Associated Lipodystrophy) — FDA Approved

In pivotal Phase 3 trials, daily tesamorelin for 26 weeks decreased visceral adipose tissue by 15.2% compared to a 5.0% increase in the placebo group. New England Journal of Medicine A 2024 study also provided the first dedicated evidence that tesamorelin remains effective in people with HIV on integrase inhibitor (INSTI)-based regimens — the current backbone of modern HIV therapy — showing significant reductions in visceral fat with no worsening of glycemic control. PubMed

2. Lipid Profile Improvements

Tesamorelin significantly reduced triglyceride levels and improved the ratio of total cholesterol to HDL cholesterol, with total cholesterol and HDL cholesterol both improving meaningfully versus placebo. New England Journal of Medicine

3. Muscle Quality and Composition

Among people with HIV who had a clinically significant decrease in visceral adipose tissue on tesamorelin, the drug was effective in increasing skeletal muscle area and density — improvements in both muscle quality and quantity. PubMed Central

4. Non-Alcoholic Fatty Liver Disease (NAFLD)

In a randomized placebo-controlled trial, tesamorelin reduced liver fat and prevented fibrosis progression in HIV-associated NAFLD over one year, making it the first strategy shown to be effective against NAFLD in the HIV population. JCI Insight Researchers found it modulated gene pathways involved in oxidative phosphorylation, inflammation, and cell division. A prospective Phase II trial with tesamorelin in NAFLD patients is also underway (NCT03375788). ScienceDirect

5. Cardiovascular Risk Reduction

A 2025 subanalysis of Phase 3 trial data published in Open Forum Infectious Diseases found that reductions in excess visceral fat with tesamorelin led to a significant reduction in forecasted cardiovascular disease risk in people with HIV — a population whose CVD risk is nearly twice that of the general population. Oxford Academic

6. Cognitive Function

A 2022 study in Neurology examined tesamorelin’s effects on cognitive performance in older adults with mild cognitive impairment, reporting improvements in executive function measures. Oath Peptides A 2025 study investigating tesamorelin’s effects on neurocognitive impairment in HIV patients represents an exciting expansion of the medication’s potential therapeutic scope, based on growing evidence that growth hormone and IGF-1 may have neuroprotective effects. Peptide

7. Metabolic Syndrome in Non-HIV Populations (Emerging)

Research is also exploring tesamorelin’s effects beyond HIV populations — studies investigating visceral adiposity reduction in non-HIV individuals with metabolic complications have shown promising early results, though these remain investigational. Oath Peptides

8. Exercise Combination Therapy (Ongoing Trials)

Ongoing clinical trials are investigating tesamorelin as an adjunct to exercise interventions for improving physical function and muscle health in HIV patients, reflecting a growing understanding that optimal outcomes require addressing multiple aspects of health rather than single targets. Peptide

Note: Tesamorelin is FDA-approved only for HIV-associated lipodystrophy. All other applications described above are off-label or investigational. Long-term safety data outside the HIV population remain limited.